29.9 C
New York
Saturday, June 13, 2026

Tag: cell

newssourceFORcompanyinformationcontent1marketreleases

MBRYONICS, ANNOUNCES OPTICAL COMMUNICATIONS BREAKTHROUGH FOR SPACE

MBRYONICS Unveils STARLIGHT, The World's First 25G/100G/400G/800G Bi-Directional Coherent Optical Transceiver for Ultra High Speed Space LinksGALWAY,  Ireland, June 9, 2026 /PRNewswire/ -- MBRYONICS,...

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson’s Disease Programme

Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease

SEL Develops High-energy-density Lithium-ion Rechargeable Battery Having Fire Resistance, Using Novel Cathode Material LCNO (TM) (Ni-doped LCO)

ATSUGI, Japan, June 9, 2026 /PRNewswire/ -- Semiconductor Energy Laboratory Co., Ltd. (hereinafter referred to as "SEL"), headquartered in Atsugi, Kanagawa Prefecture, has conducted...

SNEC 2026 | EVE Energy Secures Over 67GWh in Major Orders, Extending Its Lead in Energy Storage

SHANGHAI, June 9, 2026 /CNW/ -- From June 3 to 5, EVE Energy made a major impact at the SNEC PV Photovoltaic Power Conference &...

Sony Semiconductor Solutions to Release X-ray CMOS Sensor with Industry’s Fastest(*1) Imaging and Low-Noise Performance for Inspection and Measurement Instrumentation

High-accuracy energy measurements and photon-level data acquisition on a single chipATSUGI, Japan, June 8, 2026 /PRNewswire/ -- Sony Semiconductor Solutions Corporation (Sony) today announced...

Hyundai Motor Company and FIFA Museum Welcome Visitors to “Legacies of Champions” Fan Experience at Rockefeller Center During FIFA World Cup 2026™

Special exhibition runs June 11–July 19 at Rockefeller Center in New York CityExhibition celebrates FIFA World Cup™ history through immersive experiences, innovation and Hyundai...

CAREstream America introduces new era of science-backed innovation to deliver a new standard of quality to the US aesthetic market

CAREstream America announces an exclusive distribution partnership to bring Celltermi HS and NX Plus, an advanced probiotic-derived microbiome technology, to the US market. Celltermi...

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...

All Stars Project Launches Artistic Advisory Council for Re-Opened West 42nd Street Multi-Theatre Center

NEW YORK, June 8, 2026 /PRNewswire/ -- The All Stars Project, Inc. (ASP) announced the launch of its new Artistic Advisory Council (Council), composed...

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Solidion Technology Granted 7 New Patents on Composite Anode Materials For Batteries Targeting Humanoid Robots, Space-Based Artificial Intelligence Data Centers and the Lunar Economy

 The newly granted patents further strengthen an already globally leading portfolio of patents on anode materials for high-energy and fast-charging lithium batteriesDALLAS, June 8,...

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCell

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers